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Summary
Autosomal dominant polycystic kidney disease
(ADPKD) is genetically heterogeneous, with at least
three chromosomal loci (PKD1, PKD2, and PKD3) that
account for the disease. Mutations in the PKD2 gene,
on the long arm of chromosome 4, are expected to be
responsible for ∼15% of cases of ADPKD. Although
ADPKD is a systemic disease, it shows a focal expres-
sion, because !1% of nephrons become cystic. A feasible
explanation for the focal nature of events in PKD1, pro-
posed on the basis of the two-hit theory, suggests that
cystogenesis results from the inactivation of the normal
copy of the PKD1 gene by a second somatic mutation.
The aim of this study is to demonstrate that somatic
mutations are present in renal cysts from a PKD2 kidney.
We have studied 30 renal cysts from a patient with PKD2
in which the germline mutation was shown to be a de-
letion that encompassed most of the disease gene. Loss-
of-heterozygosity (LOH) studies showed loss of thewild-
type allele in 10% of cysts. Screening of six exons of the
gene by SSCP detected eight different somaticmutations,
all of them expected to produce truncated proteins.
Overall, 37% of the cysts studied presented somatic
mutations. No LOH for the PKD1 gene or locus
D3S1478 were observed in those cysts, which demon-
strates that somatic alterations are specific. We have
identified second-hit mutations in human PKD2 cysts,
which suggests that this mechanism could be a crucial
event in the development of cystogenesis in human
ADPKD-type 2.
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Introduction
Autosomal dominant polycystic kidney disease
(ADPKD; MIM 173900) is one of the most common
Mendelian disorders in humans and the most frequent
genetic cause of renal failure in adults. The main feature
of the disease is the bilateral progressive cystic dilation
of the renal tubules, which may lead to end-stage renal
disease (ESRD). Hepatic cysts, cerebral aneurysms, and
cardiac valve abnormalities may also be found (Gabow
1993). Although ADPKD is a systemic disease, it shows
a focal expression, because !1% of nephrons become
cystic (Baert 1978). ADPKD is a genetically heteroge-
neous condition, with at least three genes involved: (1)
PKD1, located in 16p13.3, which accounts for most
ADPKD cases (Reeders et al. 1985; Peters and Sandkuijl
1992; European Polycystic Kidney Disease Consortium
1994; Torra et al. 1996); (2) PKD2, located in 4q21–q22
(Kimberling et al. 1993; Peters et al. 1993); and (3) the
much rarer PKD3, not yet mapped (Daoust et al. 1995;
de Almeida et al. 1995). PKD1 and PKD2 genes have
been recently cloned and characterized (European Poly-
cystic Kidney Disease Consortium 1994; Burn et al.
1995; Hughes et al. 1995; International PKD Consor-
tium 1995; Mochizuki et al. 1996).
The PKD2 gene consists of 15 exons with an open
reading frame of 2,904 bp (Mochizuki et al. 1996; Hay-
ashi et al. 1997). Polycystin-2, the PKD2 gene product,
is predicted to be a 968-amino acid integral-membrane
protein with six membrane-spanning domains and in-
tracellular amino and carboxyl termini (Mochizuki et al.
1996). At present, several germline mutations have been
described in the PKD2 gene, including nonsense, splice-
site, frame-shift, and two putative missense mutations
(Mochizuki et al. 1996; Veldhuisen et al. 1997; Viribay
et al. 1997; Xenophontos et al. 1997; Pei et al. 1998;
Torra et al., in press). Most of the PKD2 mutations are
expected to produce truncated proteins, since they also
occur for mutations in the PKD1 gene. Recent studies
have demonstrated that polycystin-2 interacts with poly-
cystin-1 through its cytoplasmic carboxyl end (Qian et
al. 1997; Tsiokas et al. 1997); thus, truncatingmutations
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Figure 1 PKD2 kidney with a needle inserted into a cyst.
would interfere with this interaction. These truncating
mutations, in both PKD1 and PKD2, suggest that
ADPKD is caused by inadequate levels of polycystin (i.e.,
haploinsufficiency). The process of cystogenesis could
also be explained by a model of dominant/negative func-
tion, in which a mutated form of polycystin would in-
activate the normal polycystin produced by the normal
allele. On the basis of loss-of-heterozygosity (LOH) stud-
ies, it has been proposed that the process of cystogenesis
in PKD1 results from focal somatic second hits on the
wild-type allele (Qian et al. 1996; Brasier and Henske
1997). However, the strong immunoreactivity for po-
lycystin-1 observed in the majority of PKD1 cysts has
challenged this hypothesis (Geng et al. 1996; Ward et
al. 1996; Ibraghimov-Beskrovnaya et al. 1997; Ong et
al., 1999). Alternatively, it has been suggested that, as
polycystin-1 interacts with polycystin-2, somatic muta-
tions in PKD2 could cooperate with the germline mu-
tation in PKD1 (Qian et al. 1996). Wu et al. (1998)
showed results that support a two-hit hypothesis inmice.
Recent studies on a mouse model for PKD2 found that
mice that carry a null allele and an allele that can un-
dergo genomic rearrangements that lead to a null allele
develop renal cysts at a higher frequency than those that
are heterozygous for any of these alleles (Wu et al. 1998).
More recently, Koptides et al. (1999) showed evidence
of somatic point mutations for human PKD2 cysts, but
did not find evidence of LOH. The purpose of the present
study was to demonstrate a loss-of-function mechanism
for PKD2 in humans through the study of LOH and
point somatic mutations within the PKD2 gene.
Material and Methods
Patients and Specimens
The cysts studied were obtained from a kidney that
belonged to a patient with ADPKD who underwent an
orthotopic transplantation at age 69 years. His kidney
was removed during the transplantation procedure. This
patient belongs to a large family we had previously stud-
ied that had clear evidence of linkage to PKD2 (LOD
score 4.0) (Torra et al. 1996). This family was the only
one of our families with PKD2 in which no mutation
had been detected by heteroduplex or SSCP analyses
(Torra et al., in press). The clinical features of the persons
in this family were those typical of persons with PKD2
with late-onset disease and with ESRD at a mean age
of 72 years. The kidney was studied immediately after
removal, which took place in the Hospital Clı´nic of Bar-
celona. The study was approved by the hospital’s ethical
committee.
Preparation of Cystic Epithelial Cells and DNA
Preamplification
To avoid contamination from neighboring cells, we
followed the procedure of Qian et al. (1996) and intro-
duced some modifications. Throughout the procedure,
the kidney was placed on ice in a tray (fig. 1). To obtain
as few contaminating cells as possible, the surface of the
cyst was first rinsed with PBS. We then drained the cyst
content with a needle and a syringe. The needle was left
inserted in the cyst during the washing steps. The cavity
of the cyst was rinsed four to eight times with Ca2 and
Mg2-free PBS, until the liquid that was obtained ap-
peared to be clear. At this point, PBS/2 mM EDTA was
introduced into the cysts and was energetically pulled in
and out of the cyst several times to facilitate the de-
tachment of the epithelial cells from the basement
membrane. Only the cysts that remained intactwere con-
sidered for the study. The cells that were obtained from
the cyst cavity were suspended in PBS/2 mM EDTA and
centrifuged at 14,000 rpm for 5 min, and the super-
natant was discarded. The pellet was resuspended with
600 ml of urea solution (8 M urea, 0.3 M NaCl, 10 mM
EDTA, 10 mM TRIS, 2% SDS) and 12 ml of proteinase
K solution (10 mg/ml), incubated overnight at 37C, and
treated with a phenol/chloroform extraction. Next, 0.5
ml glycogen and 2.5 V absolute ethanol were added, and
the pellet was incubated for 1 h at 80C. After incu-
bation, it was centrifuged for 20 min at 14,000 rpm and
the supernatant was discarded. Eventually, the pellet was
dried and resuspended in 45 ml 1#TE pH 7.5.
To increase the amount of DNA for subsequent stud-
ies, the material obtained from cystic cells was pream-
plified. The reaction included 1–2 ml DNA, 6 ml 10#
buffer (Perkin-Elmer), 4mM DTT, 2.5 mM MgCl2, 10
mM of each dNTPs, 5 U of Taq polymerase (Perkin-
Elmer), 400 mM of each random primer (15-mer oli-
gonucleotides in which any one of the four possible bases
could be present at each position), and distilled water
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Table 1
Somatic Mutations in the PKD2 Gene in a Polycystic Kidney of
a Patient with Autosomal Dominant PKD2
Cyst
LOH for
Microsatellites Mutation Exon or Intron
C1 IVS41GrA Intron 4
C3 934insG Exon 4
C5 990delCa Exon 4
C6 D4S1542, D4S1563 PKD2 deletion Exons 1–15
C8 2236insA Exon 11
C10 D4S1542, D4S1563 PKD2 deletion Exons 1–15
C17 D4S1563 PKD2 deletion ?
C23 Y429Xb Exon 5
C25 2198del13 Exon 11
C29 1217delT Exon 5
C30 2207delT Exon 11
aMutation 990delC abolishes a BamHI restriction site.
bMutation Y429X abolishes an RsaI restriction site.
to 60 ml. PCR amplification was performed as follows:
5 min at 94C; 50 cycles: 1 min at 94C, 2 min at 37C,
and 4 min at 55C.
LOH Analysis
Each DNA sample was typed by PCR by using mi-
crosatellites D4S1542 and D4S1563 for PKD2 locus
and by using D16S663, D16S291, and KG8 [PKD1-
3′UTR] for PKD1. The distance of these flanking mark-
ers to the corresponding gene was !1 cM. Marker
D3S1478 was used as a control. The patient was infor-
mative for all the microsatellites studied. One microliter
of preamplified DNA was used for each PCR reaction.
We used 5% DMSO and 1.5 mM (D16S663, KG8
[PKD1-3′UTR], D4S1563, D4S1542, and D3S1478) or
1 mM (D16S291) MgCl2. The PCR conditions were as
described elsewhere (Torra et al. 1996; Brasier et al.
1997). The PCR products were run on an acrylamide
gel and were silver stained (Bassam et al. 1991).
Search for PKD2 Mutations, DNA Sequencing, and
Restriction Enzyme Analysis
We analyzed exons 2, 4–6, 11, and 12 of PKD2. The
primers used for exon amplification and PCR conditions
have been described elsewhere (Hayashi et al. 1997; Vi-
ribay et al. 1997). PCR products were analyzed by SSCP.
Three microliters of denatured PCR product were com-
bined with loading buffer, were loaded into GeneGel
Excel 12.5 acrylamide gels (Amersham Pharmacia Bio-
tech), and were run according to the manufacturer’s in-
structions. The different migrations were silver stained
(Bassam et al. 1991). DNA samples with abnormal mi-
grations were sequenced. PCR products were purified by
using the QIAquick PCR purification kit (Qiagen) and
were automatically sequenced by means of the Dye Ter-
minator Cycle Sequencing Ready Reaction (Perkin Elmer
Cetus) and an automatic sequencer (ABI310). To exclude
the possibility that the mutations were the result of the
preamplification step, we analyzed nonpreamplified
DNA from two cysts that harbor mutations that dis-
rupted an endonuclease recognition site (see table 1) and
confirmed the presence of the corresponding mutations.
We also preamplified and twice sequenced the other mu-
tations that do not abolish a restriction site, which con-
firmed the presence of the nucleotide changes.
DNA Dosage Assessment
Five micrograms of genomic DNA from affected and
normal individuals were digested with 50 U of EcoRI
(Boehringer-Mannheim) and run on a 0.8% agarose gel
at 40 V overnight. Southern blotting onto a nylon filter
was done according to standard protocols. DNA probes
were prepared by PCR amplification of genomic DNA,
followed by extraction of the corresponding band from
low–melting-point agarose gels. For PKD2, two probes
were obtained by amplification of part of exon 1 of the
gene with primers F42 and IR19d (Hayashi et al. 1997)
or by amplification of a fragment containing exons 11
and 12 with primers IF10 and IR3. A control DNA
probe was obtained by amplification of exon 4 of the
CFTR gene (Zielenski et al. 1991). DNA probes were
labeled with [32P]-dCTP to high specific activity by the
random hexamer primer method. Hybridizations, si-
multaneously containing one of the PKD2 probes and
the control probe, were done at 65C. The sizes of the
target EcoRI fragments were 5.2 and 5.4 kb for exon 1
and exons 11–13 of the PKD2 gene, respectively (Hay-
ashi et al. 1997), and 4.7 kb for exon 4 of CFTR (Zie-
lenski et al. 1991). The band densities of patients and
normal individuals were analyzed by densitometry.
Results
Germline Mutation
The germline mutation causing the disease in this fam-
ily had not been identified after repeated screenings of
exonic sequences and exon-intron boundaries by SSCP
or by heteroduplex analyses in previous studies (Torra
et al., in press). However, analysis with a frequent poly-
morphism recently identified within exon 1 of PKD2
(Arg28Pro, Torra et al., in press) detected an apparent
non-Mendelian segregation of alleles for this polymor-
phism in the family (fig. 2A). Thus, although most af-
fected individuals were apparently homozygous for one
allele, two affected siblings (II2 and II3) were apparently
homozygous for the other allele (fig. 2B). Densitometric
analyses of genomic EcoRI DNA digests with probes
that could detect exon 1 or exons 11–13 of PKD2 de-
tected half intensity of PKD2 in the affected subjects
(fig. 2C). This result supports a deletion that encom-
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Figure 3 LOH of alleles at microsatellites D4S1563 and
D4S1542 linked to the PKD2 gene in cysts from a patient (I3) with
ADPKD-type 2. Lanes C4–C11 correspond to cysts from patient I3.
LOH from cysts C6 and C10 is indicated with an asterisk. In both
cases the lost allele corresponds to the wild-type allele. Lymphocyte
DNA from subjects II6 (affected daughter) and I4 (spouse) is also
shown. Patient numbers correspond to those shown in figure 2. LOH
was determined by visual comparison of signals obtained from am-
plification of cysts and control DNA. All cysts showing LOH were
typed three times, for confirmation, for both microsatellites.
Figure 2 Genomic deletion of the PKD2 gene in a family with
ADPKD-type 2. A, Pedigree of the family. Haplotypes with PKD2
intragenic and flanking markers. Hemizygosity for Arg28Pro is shown
(1: Arg, 2: Pro, -:del). Individuals with abnormal segregation of the
polymorphism are indicated with an arrow. Asterisk indicates recom-
bination among PKD2 flanking markers. B, BanII digestion of DNA
region containing the Arg28Pro polymorphism. The polymorphism
creates a new BanII restriction site, originating two fragments of 162
and 86 bp instead of the original 248-bp fragment. Asterisks indicate
affected individuals. C, EcoRI digestion Southern blot analysis of sub-
jects of the PKD2 family with a probe for exons 11–13 of PKD2.
Control hybridization was done with a probe corresponding to exon
4 of CFTR. Densitometric analysis indicated that the PKD2 subjects
(*) had approximately a half dosage of the PKD2 gene.
passes at least exons 1–13 of the gene as the germline
mutation in this family. The analysis with microsatellite
markers close to the disease gene (distance !1 cM) failed
to detect LOH, which indicates that the deletion is prob-
ably not very large (fig. 2A).
PKD2 Somatic Mutations
Large deletions.—First we performed an LOH study
with two microsatellite markers (D4S1542 and
D4S1563) flanking PKD2 in 30 cysts from a kidney of
individual I3 (fig. 2A). We found that three cysts had
lost alleles for at least one of these markers (table 1). As
expected, in all cases the allele lost corresponded to the
wild-type PKD2 gene, as determined by segregation
analysis. LOH was not always absolute, probably be-
cause of contamination from noncystic cells (fig. 3).
When the PKD2 cysts were analyzed for three micro-
satellite markers linked to or within the PKD1 gene or
with the D3S1478 marker, we failed to detect any evi-
dence of LOH.
Point mutations.—Because no evidence of LOH for
the PKD2 region was found in 27 cysts, we concentrated
on screening for subtle changes in this gene, and in the
first instance we focused on six exons. After SSCP anal-
ysis, eight cases with an abnormal migration pattern
were observed, which on sequencing corresponded to
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Figure 4 Two exon 11 PKD2 point mutations in cysts of a
patient with ADPKD-type 2. A, SSCP analysis of exon 11 of the PKD2
gene of cysts C30 and C25. B, Sequencing of exon 11 from control
and cysts C25 and C30 detected two frame-shift mutations (2207delT
in C30 and 2198del13 in C25). Sequences correspond to the reverse
strands. Nucleotide positions where mutations occur are marked with
an arrow. Sequencing of C30 detected only the mutant allele as a result
of the germline deletion at the site of the mutation. Sequencing of C25
detected both the mutated and wild-type alleles, which resulted from
contamination with noncystic cells.
eight different mutations (table 1 andfig. 4). All of them
should result in a truncated PKD2 protein, six being
frame-shift mutations due to the insertion or deletion of
one or several nucleotides—one creating a premature
stop codon and one affecting the splicing of intron 4.
In most cases, sequencing revealed only the somatic-mu-
tated allele, because the germline mutation was a dele-
tion; however, since a small amount of noncystic cells
are frequently present, in some sequences we could de-
tect traces of sequence that corresponded to the wild-
type allele (fig. 4B).
Discussion
Mutations in the PKD2 gene are expected to be re-
sponsible for ∼15% of cases of polycystic kidney disease
(Peters and Sandkuijl 1992; Torra et al. 1996). The
PKD2 disease tends to run a milder course than the more
common PKD1 disease, with longer patient survival and
slower progression toward end-stage renal failure (Par-
frey et al. 1990; Gabow et al. 1992; Ravine et al. 1992;
Wright et al. 1993; Torra et al. 1996). The search for
mutations within the PKD2 gene has proven to be a
much more efficient process than the search for the
PKD1 gene, because the PKD2 gene is smaller and is
not partially reiterated, as is the PKD1 gene. All the
germline mutations reported so far in PKD2 are small
nucleotide changes, most of which lead to truncated pro-
teins. The identification of the apparent severe mutation
that we report in this paper, which gives rise to a regular
PKD2 phenotype, confirms our previous suspicion about
the lack of genotype/phenotype correlation in PKD2
(Torra et al., in press). The mean age of ESRD for this
family is 72 years, thus being completely concordant
with the mean age of ESRD for PKD2 (Hateboer et al.
1999).
Clear evidence that somatic second-hit mutations
could be involved in the process of cystogenesis in PKD1
disease has been obtained by different authors on the
basis of LOH studies in both renal and hepatic cysts
(Qian et al. 1996; Brasier and Henske 1997; Watnick et
al. 1998). When the phenotypic similarity between types
1 and 2 of the disease is taken into account, the possi-
bility arises that this mechanism could also play a role
in PKD2. Evidence in favor of this hypothesis has been
presented in a study with a mouse model for PKD2 (Wu
et al. 1998) and, more recently, in human PKD2 cysts
(Koptides et al. 1999). To confirm the existence of this
phenomenon in humans, we studied 30 renal cysts from
a patient carrying a germline deletion in the PKD2 gene.
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We obtained evidence of LOH in at least three cysts and
demonstrated that the wild-type allele was deleted. Since
the rate of LOH detected was too low (10%) to fully
explain the two-hit theory, we decided to search for point
mutations within the PKD2 gene that could account for
a second hit. Because about 70% of the germline mu-
tations in PKD2 have been found in exons 2, 4–6, 11,
and 12, SSCP analysis was done for these exons. In this
search, we found eight new somatic mutations within
the PKD2 gene. The results presented here demonstrate,
for the first time, the occurrence of somatic mutations
within the PKD2 gene and suggest that PKD2 in humans
occurs through a molecular recessive mechanism. For
somatic alterations in renal cysts, we have found LOH
in 3 of 30 cysts and eight point mutations in the re-
maining 27 cysts. All these mutations are probably in-
activating, because they are expected to produce trun-
cated proteins. Although the analysis did not cover the
whole PKD2 gene, the mutational events detected ac-
count for 37% of PKD2 cysts in the current study. The
remaining cysts may have mutations in other regions of
the PKD2 gene, or perhaps LOH is masked by contam-
ination from noncystic cells.
Renal epithelial cells have been demonstrated to be a
frequent target tissue for somatic mutation. Martin et
al. (1996) demonstrated that somatic mutation in renal
epithelial cells constitutes a frequent event. Renal epi-
thelial cells may be the target of somatic mutations for
several reasons: (1) they are metabolically active and
consume large amounts of oxygen; (2) they perform
most of the secretory and resorptive work to obtain the
renal filtrate; (3) they are mitotically competent, espe-
cially when an injury to the kidney occurs; and (4) they
are the cells from which a primary renal tumor and
adenocarcinoma arise. An important question, then, is
whether the observed LOH in this PKD2 kidney is spe-
cific for the PKD2 gene. To prove whether LOH was
specific for the PKD2 gene, we tested one microsatellite
from a region in chromosome 3 (D3S1478), which is
frequently deleted in human tumors (Brasier and Henske
1997), but we did not find any LOH for this marker in
the studied cysts. Another possibility is that somatic mu-
tations in the PKD1 gene were also involved in
PKD2–cyst formation, but we did not observe any LOH
for PKD1-linked markers in PKD2 cysts. Conversely,
we failed to detect any LOH for PKD2 markers in 60
cysts from patients with PKD1 (data not shown). These
data suggest that the observed somatic alterations were
specific to the PKD2 gene.
Although somatic second hits in PKD1 cysts have
been demonstrated (Qian et al. 1996; Brasier and Hen-
ske 1997), the strong immunoreactivity for polycystin-
1 observed in most PKD1 cysts has challenged current
thinking about its role in cystogenesis (Geng et al. 1996;
Ward et al. 1996; Ibraghimov-Beskrovnaya et al. 1997).
As in the case for PKD1, Ong et al. (1999), by working
with samples from the PKD2 kidney presented here,
have found staining for polycystin-2 in ∼85% of cysts,
although 25% of them were partial positives. The rest
of the samples were not immunoreactive, which suggests
the presence of a second PKD2 somatic mutation. Per-
haps the only way these findings can be reconciled with
the two-hit hypothesis would be if the somaticmutations
were predominantly missense changes that maintain the
epitope that the antibody is directed against. However,
the mutations detected here cause either a loss of the
gene product or truncated proteins that lack the carboxyl
end. Moreover, the germline mutation in this case is a
large deletion, which probably fails to produce a target
for the antibody. Unfortunately, our results do not offer
a satisfactory explanation to the immunoreactivity for
polycystin-2 observed in those cysts. Alternatively, it can
be speculated that somatic mutations are not necessary
for cyst formation but arise later and confer an advan-
tage on the mutant cell such that it repopulates the grow-
ing cyst. Further studies will be necessary to provide an
explanation to this paradox.
Our data reveal that a molecular recessive mechanism
is implicated in the process of cystogenesis for PKD2
disease. Polycystin-2 seems to be a member of a super-
family of proteins that are involved in the regulation of
renal epithelial cell growth. Thus, the loss of both copies
of an ADPKD gene disrupts this cascade and causes
hyperplasia of a given cell, which results in the formation
of a cyst. This fact has important implications for the
understanding of the pathophysiology of the disease and
the development of new strategies to prevent or retard
the progressive formation and enlargement of cysts. It
remains to be answered whether or not other noncystic
features of ADPKD (types 1 and 2), such as intracranial
aneurysms, also arise from a second-hit mechanism.
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